Advances in Medicinal Chemistry of Estrogen-related Receptor Alpha (ERRα) Inverse Agonists

Abstract: Estrogen-related receptor alpha (ERRα), a member of the nuclear receptor superfamily, is strongly expressed in breast cancer cells. Its overexpression is associated with poor prognosis in tri-ple-negative breast cancer (TNBC). ERRα expression could be inhibited by the downregulation of upstream oncogenic growth factors mTOR, HER2, and PI3K. Low expression of ERRα could sup-press the migration and angiogenesis of tumor cells by inhibiting the activity of its downstream sig-nals VEGF and WNT11. Studies have confirmed that ERRα inverse agonists can inhibit ERRα ex-pression to treat breast cancer. Inverse agonists of ERRα could disrupt the interactions of ERRα with its coactivators and inhibit tumor development. Existing ERRα inverse agonists have shown moderate efficacy in inhibiting the growth of breast cancer cells. Clinical inverse agonists of ERRα have not been found in the literature. This review focuses on the research progress and the structure-activity relationship of ERRα inverse agonists, providing guidance for the research and discovery of new anti-tumor compounds for TNBC.